Guggenheim Reaffirms “Buy” Rating for Savara (NASDAQ:SVRA)

Savara (NASDAQ:SVRA)‘s stock had its “buy” rating reiterated by equities researchers at Guggenheim in a research report issued on Wednesday, MarketBeat Ratings reports. They currently have a $8.00 price objective on the stock, down from their previous price objective of $9.00. Guggenheim’s target price suggests a potential upside of 274.71% from the stock’s previous close.

SVRA has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Savara in a research note on Friday, March 28th. Wells Fargo & Company reduced their price target on Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.17.

Savara Trading Up 10.1%

Shares of SVRA stock opened at $2.14 on Wednesday. The business’s 50 day moving average is $2.94 and its two-hundred day moving average is $2.97. Savara has a twelve month low of $1.89 and a twelve month high of $5.11. The company has a market capitalization of $369.01 million, a P/E ratio of -4.97 and a beta of 0.44. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). Equities analysts forecast that Savara will post -0.45 EPS for the current year.

Institutional Trading of Savara

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Savara by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company’s stock worth $25,512,000 after purchasing an additional 365,959 shares in the last quarter. SG Americas Securities LLC boosted its position in Savara by 14.0% during the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock worth $158,000 after purchasing an additional 6,330 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Savara by 23.9% during the third quarter. JPMorgan Chase & Co. now owns 69,490 shares of the company’s stock worth $295,000 after purchasing an additional 13,420 shares in the last quarter. Geode Capital Management LLC boosted its position in Savara by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 2,784,037 shares of the company’s stock worth $8,549,000 after purchasing an additional 57,187 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in Savara by 6.1% during the fourth quarter. Deutsche Bank AG now owns 927,595 shares of the company’s stock worth $2,848,000 after purchasing an additional 53,054 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.